The School of the Art Institute of Chicago announced the appointment of Rob Flot as the next vice president and dean of ...

AstraZeneca (NASDAQ:AZN) said on Friday that its gastric cancer treatment, IMFINZI, demonstrated a statistically significant ...

Atria Investments Inc lifted its holdings in iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 53.7% during the ...

Overall survival at 3 years was 57.4% and 50.7% in the FLOT and preoperative-chemoradiotherapy groups, respectively, with a median follow-up of 55 months. Jens Hoeppner, MD, from Bielefeld ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...